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provided the original work is properly cited.The increasing effectiveness of new disease-modifying drugs that suppress
disease activity in multiple sclerosis has opened up opportunities for
regenerative medicines that enhance remyelination and potentially slow disease
progression. Although several new targets for therapeutic enhancement of
remyelination have emerged, few lend themselves readily to conventional drug
development. Here, we used transcription profiling to identify mitogen-activated
protein kinase (Mapk) signalling as an important regulator involved in the
differentiation of oligodendrocyte progenitor cells (OPCs) into oligodendrocytes.
We show in tissue culture that activation of Mapk signalling by elevation of
intracellular levels of cyclic adenosine monophosphate (cAMP) using adminis-
tration of either dibutyryl-cAMP or inhibitors of the cAMP-hydrolysing enzyme
phosphodiesterase-4 (Pde4) enhances OPC differentiation. Finally, we demon-
strate that systemic delivery of a Pde4 inhibitor leads to enhanced differentiation
of OPCs within focal areas of toxin-induced demyelination and a consequent
acceleration of remyelination. These data reveal a novel approach to therapeutic
enhancement of remyelination amenable to pharmacological intervention and
hence with significant potential for translation.Institute, and Anne
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Enhancing the regeneration of myelin sheaths in the central
nervous system has been identiﬁed as an important therapeutic
strategy to ameliorate the devastating consequences of persistent
demyelination (Franklin & Ffrench‐Constant, 2008; Kotter
et al, 2011). Myelin sheaths provide the structural basis for
saltatory signal conduction and provide trophic support that
helps maintain axonal integrity. Thus, loss of myelin sheaths
(demyelination) results acutely in a conduction block (Franklin
& Ffrench‐Constant, 2008; Nguyen et al, 2009) and ultimately in
axonal degeneration (Bitsch et al, 2000; Nikic et al, 2013). Myelin
regeneration, or remyelination, is mediated by multipotent adult
stem/progenitor cells (Kotter et al, 2011; oligodendrocyte
progenitor cells, OPCs) that are recruited into areas of
demyelination where they engage axons, and differentiate
into myelin forming oligodendrocytes (Franklin & Ffrench‐
Constant, 2008; Kotter et al, 2011; Zawadzka et al, 2010). Inis is an open access article under
ion and reproduction in any medium,
EMBO Mol Med (2013) 5, 1918–1934
Research Articlewww.embomolmed.org
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as multiple sclerosis (MS), remyelination frequently fails
because of a declining efﬁciency in OPC differentiation (Chang
et al, 2000; Kuhlmann et al, 2008; Wolswijk, 1998). Therefore,
the search for safe drugs that are able to stimulate OPC
differentiation and promote remyelination represents a major
focus in clinical neurology. Some hope derives from recent
ﬁndings such as the identiﬁcation of leucine‐rich‐repeat and
Ig‐domain‐containing 1 (LINGO‐1), the wnt pathway and
retinoic acid receptor gamma (RXR‐g) as potential therapeutic
targets (Fancy et al, 2011; Huang et al, 2011; Mi et al, 2007).
The biological process leading to OPC differentiation likely
involves a cascade of molecular events that eventually
determines the generation of mature oligodendrocytes. Implicit
in such a model is ﬁrst, the concept that the initial triggers are
fewer than the signals ultimately required for differentiation and
second, the prediction that manipulation of these early triggers
will have more profound consequences for differentiation than
later events. Thus, to identify the earliest detectable transcrip-
tional correlates of differentiation, we conducted a microarray
analysis of gene expression in primary rat OPCs undergoing
rapidmorphological changes in cell culture within a few hours of
puriﬁcation. This revealed signiﬁcant regulation of several genes
associated with the Mapk signalling pathway, leading us to
ask whether an increase in intracellular cyclic adenosine
monophosphate (cAMP), a positive regulator of Mapk signalling,
could promote OPC differentiation. We show that pharmaco-
logical inhibition of the cAMP‐hydrolysing enzyme phosphodi-
esterase‐4 (Pde4) stimulates OPC differentiation in the presence
of myelin inhibitory factors likely to be present in early‐stage MS
lesions. Finally, we demonstrate that inhibition of Pde4
promotes CNS remyelination in vivo. Our results suggest a
novel approach for the therapeutic enhancement of remyelina-
tion in chronic demyelinating disease, such as MS (Barkhof
et al, 2010).RESULTS
Transcription proﬁling identiﬁes Mapk signalling as potential
early regulator of OPC differentiation
To identify early transcriptional events that initiate OPC
differentiation into oligodendrocytes, transcriptional proﬁling
was performed on primary rat OPC monocultures directly after
puriﬁcation and following differentiation for 4 and 12 h.
Differential expression between sample groups was assessed
using the moderated t‐test with p‐value correction for multiple
testing at a false discovery rate (FDR) threshold of 5% (q< 0.05).
Among other ﬁndings this revealed that several members of the
mitogen‐activated protein kinase (Mapk) pathway were differ-
entially regulated during early stages of OPC differentiation.
For example, Mapk phosphatase‐1 (Mkp‐1/Dusp1), which
dephosphorylates two key members of classical Mapk and
Jnk/p38Mapk signalling pathways, Erk and p38Mapk (Fragoso
et al, 2007; Kaiser et al, 2004; Sanchez‐Perez et al, 1998), was
found to be rapidly down‐regulated within 4 h of initiation of
differentiation (Supporting Information Fig 1).EMBO Mol Med (2013) 5, 1918–1934 Given that the Mapk pathway has been previously implicated
in the differentiation of OPCs (Fragoso et al, 2007) and of other
cell lineages (Nebreda & Porras, 2000; Ono & Han, 2000), we
explored the regulation of members of the Mapk signalling
pathway in the process of myelin regeneration in vivo by
examining dynamic changes in expression of genes associated
with this pathway using previously published transcriptome
data of CNS remyelination (Huang et al, 2011). This revealed
changes in several genes associated with this pathway at the
stage of remyelination at which OPC differentiation is initiated
(Supporting Information Fig 1).
Phosphorylation of Erk1/2, p38Mapk and Creb1 in OPCs is
impaired in presence of myelin‐associated inhibitors
The Mapk pathway involves both classical Erk‐mediated and
p38Mapk signalling. To investigate which part of Mapk
signalling is primarily involved in OPC differentiation, we
examined the effects of suppressing OPC differentiation on Erk
and p38Mapk activation. To do this, we cultured OPCs on tissue
culture plates coated with CNS myelin protein extract (MPE),
which have previously been shown to contain proteins
profoundly inhibitory to OPC differentiation (myelin‐associated
inhibitors, MAI) (Kotter et al, 2006; Robinson & Miller, 1999).
This approach also has pathophysiological relevance because it
is likely that uncleared myelin debris in early MS lesions
contributes to remyelination failure (Kotter et al, 2011). OPCs
were cultured for 24 h in differentiation medium in the presence
or absence of MPE. Assessment of Erk and p38Mapk
phosphorylation demonstrated a signiﬁcant reduction of Erk1/
2 and p38 Mapk activity in the presence of myelin associated
inhibitors (Fig 1A and B).
The transcription factor Creb1 is a downstream effector of
p38Mapk (Foulkes et al, 1991; Krebs et al, 1997) and Erk1/2
(Esparza et al, 2008; Zubenko & Hughes, 2010). Because Mapk
activation of Creb1 has been implicated in the differentiation of
various cells, including OPCs (Cuadrado & Nebreda, 2010; Di
Giacomo et al, 2009; Gonzalez & Montminy, 1989; Sato‐Bigbee
et al, 1994) we assessed Creb1 activation in differentiating OPCs.
This revealed an increase in Creb1 phosphorylation associated
with OPC differentiation (Supporting Information Fig 2), which
was impaired in the presence of MAI (Fig 1C).
To functionally test the role of Erk1/2, p38Mapk and Creb1 in
OPC differentiation, OPCs were cultured in the presence of
pharmacological inhibitors. When Erk1/2 signalling was
inhibited, differentiation was arrested at a pre‐myelinating stage
of the oligodendrocyte lineage in which there was a reduction in
Mbp expression by O4 expressing cells (Fig 2A–C). In contrast,
inhibition of p38Mapk resulted in a signiﬁcant reduction of both
O4 andMbp immunoreactivity, indicating a differentiation block
at earlier stages of the oligodendrocyte lineage (Fig 2D–F). The
most pronounced inhibition of both O4 and Mbp expression was
detected when the interaction of Creb1 with its binding partner
Creb binding protein (CBP) (Delghandi et al, 2005; Weiss, 1975)
was prohibited using an CBP‐Creb interaction inhibitor
(Whitaker et al, 2008) (Fig 2G–I).
To investigate whether Erk1/2 and p38Mapk are directly
involved in the phosphorylation of Creb1, we conducted an2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1919
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Figure 1. Inhibition of OPC differentiation by MAI is regulated by phosphorylation of Erk1/2, p38Mapk and Creb1.
A–C. Top, representative blots of phosphorylated (p-) protein, re-probed for total (t-) protein levels, of (A) Erk1/2, (B) p38Mapk and (C) Creb1. Bottom, relative
optical-density-based (ROD) quantification of phosphorylated to total protein ratios of Erk, p38Mapk and Creb1 on control (poly-L-Lysine, PLL) substrates
and in the presence of MAI (MPE). Student t-tests: (A) n¼3; p<0.05; PLL:0.61770.1166; MPE: 0.34060.01203; B) n¼3; p<0.01; PLL:
0.34380.04692; MPE: 0.074130.004414; (C) n¼4; p<0.01; PLL: 1.2440.07505; MPE: 0.55170.09847.
D. Proposed model of Mapk signalling during OPC differentiation: OPC differentiation is mediated by activation of Erk1/2 and p38Mapk. Erk1/2 and p38Mapk
in turn activate Creb1, which ultimately leads to OPC differentiation. The presence of MAI impairs Erk1/2 and p38Mapk activation, which results in
impairment of Creb1 phosphorylation. Themodel predicts that an increase of intracellular cAMP results in activation of p38Mapk, Erk1/2 and Creb1 activity
and ultimately promotes OPC differentiation. Error bars: SEM.
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1920in situ protein interaction assay (proximity ligation assay, PLA).
A ﬂuorescent signal generated as a result of approximation
indicated a direct interaction between of phosphorylated (p‐)
Erk1/2 and p‐Creb1 (Fig 3A–C), and between p‐p38Mapk and
p‐Creb1 (Fig 3D–F). Creb1 therefore seems to be directly
phosphorylated by Erk1/2 and p38Mapk in differentiating OPCs.
These ﬁndings suggest a model in which activation of Erk1/2
and p38Mapk triggers activation of Creb1 leading to OPC
differentiation (Fig 1D). In contrast, MAI impair p38Mapk
activation, which results in impaired Creb1 phosphorylation and
hence an inhibition of differentiation. The model predicts that
interventions that induce p38Mapk, Erk1/2 and Creb1 activity
will promote OPC differentiation and ultimately enhance
remyelination.
Elevation of intracellular levels cAMP by dbcAMP or inhibition
of phosphodiesterease‐4 induces OPC differentiation in the
presence of myelin‐associated inhibitors
Erk1/2/p38Mapk activity can be induced by increasing levels of
the intracellular second messenger cAMP. This can be achieved
through at least two independent mechanisms: ﬁrst, a direct
interaction between cAMP and Creb1, and second by activation
of the cAMP‐dependent kinase Pka, which in turn phosphor-
ylates Erk1/2 (Costes et al, 2006; Smith et al, 2010) and p38Mapk
(Cuadrado & Nebreda, 2010; Delghandi et al, 2005; Gonzalez &
Montminy, 1989).
To test whether increasing intracellular levels of cAMP
overcome the inhibitory effects of MAI, we ﬁrst added dibutyryl
cAMP (dbcAMP, a membrane permeable cAMP analogue) to the
culture medium. Differentiation was assessed on the basis of O4
and Mbp expression, and revealed an increase in OPC
differentiation after 48 h of culture (Fig 4A–D) in the presence
of dbcAMP. 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.We next increased intracellular cAMP levels by inhibiting the
cAMP‐hydrolysing activity of Pde4 (Weiss, 1975), of which OPCs
express several subtypes (Whitaker et al, 2008). Recently, a
number of different Pde4 inhibitors have been used in preclinical
studies (Nials et al, 2011; Schafer et al, 2010) and in clinical trials
(Shih et al, 2010; Spina, 2008). To test whether small‐molecule
inhibitors of Pde4 can promote OPC differentiation in the
presence of OPC differentiation inhibitors, Pde4 inhibitors
(rolipram, milrinone, irsogladine, zaprinast and rottlerin) were
added to the medium at various concentrations (Supporting
Information Fig 3). All inhibitors tested signiﬁcantly induced
OPC differentiation in the presence of MAI. For example, the
differentiation‐inducing effects of rolipram, a drug initially
developed as an anti‐depressant, at a concentration of 0.5mM
were comparable to the effects of dbcAMP treatment (Fig 4A).
Rolipram treatment resulted in an increase in the number and
complexity of OPC processes, a morphological change associated
with differentiation (Fig 4J–L).
An assessment of myelin basic protein (Mbp) mRNA
expression using quantitative reverse transcriptase PCR
(qRT‐PCR) relative to b2‐microglobulin mRNA (an internal
control used for normalization) demonstrated that rolipram
signiﬁcantly increased the expression of Mbp, a marker
expressed by mature myelin forming oligodendrocytes
(Fig 4H). Importantly, terminal deoxynucleotidyl transferase‐
mediated biotinylated UTP nick end labelling (TUNEL) assays
did not reveal differences in apoptosis between control and
rolipram‐treated OPCs plated on MPE, thus ruling out differ-
ences in cell survival (Supporting Information Fig 4). Finally, we
assessed whether dbcAMP or rolipram could promote the
differentiation of OPCs cultured on control substrates. No
signiﬁcant change in MBP expression was seen following
treatment (Fig 4M–P).EMBO Mol Med (2013) 5, 1918–1934
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Figure 2. Erk1/2, p38Mapk and Creb1 play a functional role during OPC differentiation.
A. Bar graph showing the decrease of Mbp-positive oligodendrocyte lineage (OL) cells after 2 days in differentiation medium in the presence of an Erk1/2
inhibitor. ANOVA: O4 p>0.05, MBP p<0.001; Dunnett’s post hoc test PLL versus PLL with ERK1/2 inhibitor: p<0.0001; mean decrease: O4¼11%;
Mbp¼67%.
D. Bar graph demonstrating a significant decrease of O4/Mbp-positive OL cells after treatment with a p38 inhibitor. ANOVA: (O4 p<0.0001, Mbp
p<0.0001; Dunnett’s post hoc test PLL versus PLL with p38Mapk inhibitor: p<0.0001; mean decrease: O4¼49%, Mbp¼66%.
G. Bar graph indicating a significant decrease of O4 immunoreactivity and a complete loss of Mbp expression in the presence of a Creb inhibitor. ANOVA:
O4 p<0.0001, MBP p<0.0001; Dunnett’s post hoc test PLL versus PLL with Creb1 inhibitor: p<0.0001; mean decrease: O4¼87%,
Mbp¼100%. Error bars: SEM.
B,C,E,F,H,I. Representative images of cells immunolabelled for O4 (red) and MBP (green) on control substrates and cultured in differentiation medium
supplemented with ERK1/2 inhibitor. Scale bar¼30mm.
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Erk1/2, p38Mapk and Creb1 in presence of myelin‐associated
inhibitors
To conﬁrm that inhibition of Pde4 acts via the proposed
mechanism the phosphorylation status of Erk1/2, p38Mapk and
Creb1 was assessed in OPCs cultured in the presence of MAI and
treated with rolipram. This demonstrated a signiﬁcant increase
in the phosphorylation of Erk1/2, p38Mapk and Creb1 in
rolipram‐treated cells (Fig 5A–C). Furthermore, when OPCs
were cultured on MAI‐inhibitory substrates and treated withEMBO Mol Med (2013) 5, 1918–1934 rolipram in combination with inhibitors of Erk1/2, p38Mapk and
Creb negative effects on OPC differentiation were observed:
inhibition of Erk1/2 resulted in reduced numbers of Mbp‐
positive cells (Fig 5D–F) and inhibition of p38Mapk in a
signiﬁcant reduction of both O4 and Mbp immunoreactivity
(Fig 5G–I). The most extensive reduction of both O4 and Mbp
expression was again detected when the interaction of Creb1
with Cbp was impaired (Fig 5J–L). These ﬁndings suggest that
Erk1/2, p38Mapk and Creb1 play a role with respect for the
differentiation‐inducing effects of rolipram.2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1921
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Figure 3. In situ PLA conﬁrms direct interactions of p‐Erk1/2 and p‐p38Mapk with p‐Creb1 during OPC differentiation. To explore interactions between
phosphorylated (p-) Creb1 to (p-) Erk1/2 and (p-) p38 an in situ PLA was conducted. Each interaction complex detected by PLA is visualized with a fluorescent
signal. DNA was counterstained by Hoechst 33342 (blue).
A–C. Complexes between endogenous p-Erk1/2 and p-Creb1 were detected in the nucleoplasm and cytosol of differentiated oligodendrocytes.
D–F. Similarly, complexes between p-p38 and p-Creb during oligodendrocyte differentiation were detected.
G. Quantification of interaction complexes indicated increased interaction between p-38Mapk and p-Creb1 as compared to p-Erk1/2 and p-Creb1.
H,I. As a negative control a PLA was conducted in the absence of p-Erk1/2 or p-p38Mapk antibodies. The absence of signal demonstrates the specificity of the
assay. Scale bar¼20mm.
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1922OPCs express Erk1/2, p38Mapk and Creb1 in remyelinating
lesions
To investigate whether OPCs express Mapk‐pathway associated
molecules in remyelinating lesions focal demyelination was
induced in the cerebellar white matter of adult rats by the direct
injection of ethidium bromide (a well‐characterized model of
toxin‐induced demyelination thatundergoes an age‐dependent
stereotypical pattern of spontaneous remyelination (Woodruff &
Franklin, 1999, Sim et al, 2002). Sections of lesions at 14 days
post‐lesion induction (dpl) were double‐stained with antibodies
against p‐Erk1/2 or p‐p38Mapk and Nkx2.2, a marker for
activated OPCs (Supporting Information Fig 5A–F). This
demonstrated that activated Erk1/2 and p38Mapk were present 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.in Nkx2.2‐positive OPCs. Furthermore, active Creb1 was
detected in the majority of cells positive for the oligodendroglial
lineage marker Olig2 within the lesions (Supporting Information
Fig 5G–I).
Inhibition of Pde4 promotes priming and differentiation of
OPCs in vivo
To assess the effects of Pde4 inhibition on remyelination,
rolipram was administered via a subcutaneous minipump
starting 3 days post lesion induction (dpl) and the lesions
analysed at 7, 14 and 21dpl. Assessment of the lesion
size revealed no signiﬁcant differences between the groups at
the various time points (Supporting Information Figs 6 and 7). TheEMBO Mol Med (2013) 5, 1918–1934
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B–G. Representative images of cells immunolabelled for O4 (red) and Mbp (green) on PLL (B,E), on MPE (C,F) and onMPE treated with dbcAMP (D) or rolipram (G).
Nuclei were visualized with Hoechst (blue).
H. Ratio of mRNA levels of myelin basic protein (Mbp) versus b2-microglobulin (b2-MG) in cells cultured on PLL, MPE and on MPE in the presence of rolipram,
determined by RT-qPCR. n¼3; Dunnet’s post hoc test MPE versus MPEþ rolipram: p<0.05.
I–L. Morphological assessment of OPCs plated on (J) PLL, (K) MPE, (L) MPE plus 0.5mM rolipram and dbcAMP on the basis of the following categories: I, mono/
bipolar; II, primary branches; III, secondary branches; IV, membranous sheaths.
M–P. Bar graph and representative images indicating that treatment of OPCs cultured on PLL control substrates with dbcAMP or rolipram does not result
accelerate the differentiation process. ANOVA: (O4 p>0.05, Mbp p>0.05; Dunnett’s post hoc test PLL versus PLLþ dbcAMP: p>0.05; mean Increase:
O4¼7%, Mbp¼34%; PLL versus PLLþRoli: p>0.05; mean Increase: O4¼0%, Mbp¼18%. Error bars: SEM. Scale bars in B–G¼50mm, in J–L¼30mm, in
N–P¼50mm.
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Yasir A. Syed et al.expression of Pdgfra, an OPC marker, and Nkx2.2, a transcription
factor associatedwithOPCs that are primed for differentiationwas
visualized by in situ hybridization and quantiﬁed (Fancy
et al, 2004; Kotter et al, 2006). Inhibition of Pde4 affected neither
the overall number of undifferentiated OPCs within the lesions as
compared with controls at 7 and 14dpl (Fig 6A–E), nor the
number of Olig2þKi67þ proliferating OPCs (Fig 7A and D–I).
However, rolipram treatment signiﬁcantly increased the number
of Nkx2.2‐expressing cells compared with controls at 7 dpl,
indicating that inhibiting Pde4 enhances OPC priming (Fig 6F–J).
To detect differences in the number of differentiated
oligodendrocytes, cells were visualized by in situ hybridization
for Proteolipid protein (Plp), a marker of mature oligodendrocytes
(Pfeiffer et al, 1993). Rolipram treatment signiﬁcantly increased
the number of Plp‐expressing cells at 14 dpl (Fig 6K–O).
Inhibition of Pde4 enhances remyelination following
experimental demyelination
In white matter tracts such as the caudal cerebellar peduncle
(CCP), which contains a large proportion of large diameter axons
(Woodruff & Franklin, 1999) remyelination can be reliably
distinguished from myelination on the basis of thinner myelin
sheaths, detectable on toluidine blue‐stained semi‐thin resin
sections and electron micrographs (Blakemore, 1974). Whereas
in control animals remyelination was restricted to a thin rim at
the edge of the lesion in areas in which myelin debris was
cleared, rolipram treatment increased the number of remyeli-
nated axons around the lesion border signiﬁcantly and patches
of remyelination were found deeper within the lesions.
Investigator‐blind rank analysis of the extent of remyelination
demonstrated that inhibition of Pde4 treatment signiﬁcantly
increased the number of remyelinated axons in the lesions
(Fig 8A). These ﬁndings were conﬁrmed by independent
quantiﬁcation of remyelinated axons and demyelinated axons
in 1500 low power EM ﬁelds (Fig 8B). These data suggested
that rolipram treatment increased the rate of remyelination,
predicting that at a stage before remyelination is complete the G‐
ratio in the treated group will be lower (myelin sheath thicker).
We therefore preformed a G‐ratio analysis at 14 days (i.e. before
remyelination is complete) and found that the group treated with
the Pde‐4 inhibitor had a lower G‐ratio than the control‐treated
group (Fig 8G and H).Figure 5. Promoting OPC differentiation by inhibition of Pde4 depends on Er
A–C. Assessment of Erk1/2, p38Mapk and Creb1 phosphorylation by immu
bottom, quantification based on ROD. (A) Erk1/2: n¼3; t-test: p<0.0
p38Mapk: n¼3; t-test: p<0.05; MPE:1.2170.4094, MPEþ rolipram
MPEþR: 0.75600.03277.
D. Bar graph showing the percentage of O4/Mbp-positive cells cultured o
O4 and Mbp expression but addition of a specific Erk1/2 inhibitor bl
p<0.001; Dunnett’s post hoc test MPEþR versus MPEþRþ ERK1/2
G. Bar graph demonstrating that the percentage of O4/Mbp-positive posi
following treatment with a specific pharmacological inhibitor against
hoc test MPEþR versus MPEþRþp38Mapk inhibitor: p<0.0001; O
J. Bar graph indicating that the percentage of O4/Mbp-positive positive c
Creb1 inhibitor decreases below levels of cells plated on MPE. n¼3; A
versus MPEþRþCreb1 inhibitor: p<0.0001, mean decrease O4¼82
E,F,H,I,K,L. Representative images of cells immunolabelled with O4 (red) and Mb
EMBO Mol Med (2013) 5, 1918–1934 Inhibition does not alter the innate immune response
The innate immune system plays an important role in myelin
regeneration (Kotter et al, 2001). As rolipram can also exert
effects on inﬂammatory processes, albeit at higher concen-
trations than the ones used in the present study (Mendes
et al, 2009), the presence of macrophages within the lesion was
assessed by in situ hybridization for macrophage scavenger
receptor type B (Msr‐B). Levels of Msr‐B‐expressing cells did not
differ between the groups at 7 and 14 dpl, indicating that
rolipram did not affect the macrophage response (Fig 9A–C).
Similarly, assessment of Iba1 immunoreactivity did not show
any differences in the levels of macrophages within remyelinat-
ing lesions (Fig 9D–F).
To assess whether rolipram treatment induced the phagocytic
clearance of myelin breakdown products that accumulate
following EB‐induced demyelination and inhibit OPC differenti-
ation (Kotter et al, 2006), sections were stained with Oil red O,
which revealed neutral lipids accumulating following myelin
phagocytosis in macrophages. Blinded ranking analysis did not
reveal signiﬁcant differences between rolipram‐treated and
control animals (Fig 9G–I).
Inhibition of Pde4 does not inﬂuence injury levels of axons
Pde4 is known to modulate axon outgrowth (Hannila &
Filbin, 2008) and potentially their survival (Beaumont
et al, 2009). We therefore investigated whether rolipram
treatment altered the level of axonal damage following
stereotactic administration of EB in which some axonal damage
occurs (Woodruff & Franklin, 1999), by immunohistochemical
analysis of non‐phosphorylated neuroﬁlament (Smi32)
(Fig 10A–C) and anti‐amyloid precursor protein (App) expres-
sion (Fig 10D–F). Inhibition of Pde4 did not result in detectable
changes in the expression of either marker of axonal injury.DISCUSSION
The present study identiﬁes cAMP‐Erk1/2/p38Mapk‐Creb1
signalling as a functionally important intracellular signalling
cascade for CNS remyelination that is regulated at the earliest
stages of OPC differentiation. These data complement previous
studies demonstrating a role for Erk2 and p38Mapk (Chewk1/2, p38Mapk and Creb1 activity.
noprecipitation in response to rolipram treatment. Top, representative blots;
5; MPE: 0.34060.01203, MPEþ rolipram (MPEþR): 0.88160.04381; (B)
: 2.7880.4606; (C) Creb1: n¼5; t-test: p<0.001; MPE: 0.59720.03408;
n MPE and induced with 0.5mM rolipram. Treatment with rolipram promotes
ocks the differentiation-inducing effects: n¼3; ANOVA: O4 p>0.05, MBP
inhibitor: p<0.001; mean decrease O4¼35%; mean decrease Mbp¼76%.
tive cells in the presence of MPE and induced with 0.5mM rolipram decreases
p38Mapk: n¼3; ANOVA: O4 p<0.0001, MBP p<0.0001; Dunnett’s post
4 mean decrease¼42%; Mbp mean decrease¼87%.
ells in the presence of MPE, induced with 0.5mM rolipram and treated with a
NOVA: O4p<0.0001, MBP p<0.0001; Dunnett’s post hoc test MPEþR
%; mean decrease Mbp¼100%.
p (green). Error bars: SEM. Scale bar¼30mm.
2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1925
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Figure 6. Inhibition of Pde4 primes OPCs and promotes OPC differentiation.
A. Scatter plot indicating that the number of Pdgfr-a-positive cells/mm2was comparable at 7 and 14 days post lesion induction in rolipram and vehicle
treated controls. ANOVA p>0.1, Pdgfr-a: 7d control n¼13, 7 days rolipram n¼13, 14 days control n¼9, 14 days rolipram n¼9.
F. Scatter plot demonstrating a significant increase in the number of primedNkx2.2-positive OPCs in rolipram treated animals compared to controls at
7d post lesion induction. Nkx2.2: 7 days control n¼12, 7 days rolipram n¼14, 14 days control n¼9, 14 days rolipram n¼8, ANOVA: p<0.0001,
Dunnett’s post hoc test 7 days control versus 7 days rolipram p<0.001.
K. Scatter plot showing a significant increase in the number of Plp-positive mature oligodendrocytes in the lesions of rolipram treated animals. Plp:
7 days control n¼13, 7 days rolipram n¼13, 14 days control n¼9, 14 days rolipram n¼9, ANOVA p<0.001, Dunnett’s post hoc test 14 days
control versus 14 days rolipram p<0.01.
B–E,G–J,L–O. Representative sections labelled by in situ hybridization for (B–E) Pdgfr-a, G–J) Nkx2.2, and (L–O) Plp at 7 and 14 days post lesion induction.
Scale bar¼200mm.
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1926et al, 2010) as positive regulators of oligodendrocyte differentia-
tion in vitro and during developmental myelination. Loss of
ERK2 attenuates OPC differentiation and leads to a delay but not
a complete arrest in the appearance of differentiated oligoden-
drocytes in vivo (Fyffe‐Maricich et al, 2011). Similarly, p38Mapk
inhibition decreases OPC differentiation and Mbp expression
without effecting either proliferation or survival (Chew
et al, 2010). Reporter assay studies have demonstrated that
p38MAPK activity up‐regulates the activity and/or expression of
transcription factors that can bind the 2 kb mouse MBP
promoter. However, p38MAPK can also antagonize ERK, JNK,
c‐Jun phosphorylation. We found that treatment of OPCs in the
absence of MAIs with rolipram or cAMPwas not able to promote
differentiation. It is therefore unclear whether the present
strategy would be able to promote developmental myelination.
The ﬁnding that OPC differentiation inhibitors present in
myelin, which may also form part of the environment in acute
demyelinating lesions, negatively regulate cAMP‐p38Mapk‐
Creb1 signalling supports the notion that Mapk signalling plays
a functional role in the process of CNS remyelination. More
importantly, we found that increasing intracellular cAMP can 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.overcome the inhibitory effects of MAI and stimulate oligoden-
drocyte lineage progression.
The sequential nature of the Erk1/2‐p38Mapk‐Creb1 cascade
provides multiple points at which the response are regulated by
phosphorylation and dephosphorylation and the possibility
of tweaking the pathway by pharmacological intervention as to
promote oligodendrocyte differentiation in presence of extracel-
lular inhibitors.
cAMP signalling also plays a major role in the regulation of
various other cellular processes. For example, inhibition of Pde4
has been successfully used to stimulate axon regeneration
in vitro and in vivo (Pearse et al, 2004). Pde4 is a cAMP‐speciﬁc
Pde and predominant isoenzyme in themajority of inﬂammatory
cells, with the exception of platelets. Pde4 inhibitors such as
rolipram and ibudilast can have immunosuppressive and anti‐
inﬂammatory effects (Souness et al, 2000) and can delay the
entry of inﬂammatory cells into the CNS in experimental
autoimmune disease (EAE) (Fujimoto et al, 1999; Jung
et al, 1996; Martinez et al, 1999). However, it is unlikely that
these properties are relevant for the present study because the
dose of rolipram that was used to enhance remyelination in theEMBO Mol Med (2013) 5, 1918–1934
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Figure 7. Rolipram treatment does not affect OPC proliferation in remyelinating lesions.
A–C. Quantitative analysis of Ki67þ and Olig2þ cells in control and rolipram-treated lesions. Control n¼5, rolipram n¼5, Ki67þ /Olig2þ cells: t-test p<0.05,
control: 81.408.920, rolipram: 97.578.528, (B) Olig2þ cells: t-test p<0.05, control: 106419.32; rolipram: 1214239.8, (C) Ki67þ cells: t-test,
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D–I. Representative images from control and rolipram-treated lesions at 14 dpi stained for (D,G) Olig2, (E,H) Ki67 and (F,I) Ki67 and Olig2. Scale bar¼200mm, in
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Yasir A. Syed et al.present study (0.5mg/kg/day) is much lower than the dose
at which rolipram is effective as an anti‐inﬂammatory agent
(3mg/kg/day) up to 10mg/kg) (Buttini et al, 1997; Francischi
et al, 2000; Laemont et al, 1999). This view is further supported
by the absence of changes in the number of cells of the innate
immune system and the comparable levels of cell proliferation,
phagocytic activity, secretion of Il1‐b and numbers of lympho-
cytes. Furthermore, the levels of axonal damage were not
altered. Additionally, we demonstrate that newly formed myelin
sheaths were thicker in rolipram treated group compared to
control group. However, Pde4 inhibition did not have any effect
on spared myelin.
Rolipram treatment did not alter the number of Pdgfr‐a
positive, immature OPCs in remyelinating lesions. This is what
one would predict for a treatment that speciﬁcally targets OPC
differentiation since the number of immature OPCs in the lesionEMBO Mol Med (2013) 5, 1918–1934 and the number of mature oligodendrocytes is regulated
independently (e.g. Arnett et al, 2004). Nevertheless, the
number of primed Nkx2.2‐positive OPCs at day 7 increased,
indicating a response of OPCs to rolipram treatment. As in
previous studies, the increase in Nkx2.2 expression was
transient and rapidly downregulated when OPCs differentiated
into fully mature oligodendrocytes (Fancy et al, 2004). More
importantly, rolipram treatment increased the number of Plp‐
positive cells indicative of mature oligodendrocytes 14 days post
lesions induction as compared to controls. Since in experimental
model used in this study all lesions will eventually remyelinate,
these ﬁnding indicate that rolipram accelerates priming and
differentiation of OPCs into mature oligodendrocytes.
The potential for clinical translation of the present ﬁndings
is emphasized by a recent randomized controlled trial that
investigated the effects of the Pde4 inhibitor ibudilast on2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1927
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Figure 8. Inhibition of Pde4 promotes CNS remyelination.
A. Rank analysis (Scatter plot) of remyelination in CCP lesions at 14 dpl
assessed on toluidine-blue-stained semi-thin sections. Higher rank
scores indicate greater extent of remyelination; control: n¼8, rolipram:
n¼5, Mann–Whitney U test p<0.05.
B. Scatter plot representing quantification of demyelinated and remyeli-
nated axons on electron micrographs. Control: n¼7, rolipram: n¼4,
t-test: p<0.05.
C–F. Representative semi-thin and electron micrographs of (C,E) control and
(D,F) rolipram-treated animals.
G,H. Scatter plot and Box plot of G-ratios indicating that remyelinated axons
in rolipram treated animals have thicker myelin sheaths (lower G-ratios)
than remyelinated axons in controls. (G-ratios of native myelin sheaths
in both groups indicated by dotted lines.) Control: n¼34; rolipram:
n¼58; t-test; p<0.001; control: 0.85400.01211; rolipram:
0.78710.008436; Error bars: SEM. Scale bar C and D¼50mm; E and
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1928  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.relapse‐remitting MS (Barkhof et al, 2010). A number of studies
that have demonstrated beneﬁcial effects of Pde4 inhibitors
on the development of EAE; this particular study (Barkhof
et al, 2010) was designed to assess the disease‐modulating
properties of ibudilast as an alternative to current immunomod-
ulatory treatments based on interferon‐b. The study indicated
treatment with a Pde4 inhibitor was safe and well tolerated. The
primary endpoint of the study was the cumulative number of
newly active lesions on bimonthly brainMRI over 12months as a
measure of disease activity. However, similar to the present
ﬁndings, inhibition of Pde4 did not affect the inﬂammation‐
mediated formation of new active lesions and the rate of relapses
remained unchanged. However, the authors reported signiﬁcant
beneﬁcial effects of ibudilast with respect to percent brain
volume change, and over a 2‐year treatment period there were
fewer patients with conﬁrmed progression on the Expanded
Disability Status Scale (EDSS) (Barkhof et al, 2010). These
beneﬁcial effects of ibudilast were attributed to unknown
‘neuroprotective’ effects resulting from inhibition of Pde4
(Barkhof et al, 2010). Based on the present results it could be
hypothesized that this effect may in part be attributable to
enhanced remyelination. The ibudilast trial was not designed to
study remyelination in MS patients. However, the authors
reported a signiﬁcant reduction in the proportion of active
lesions that evolved into persistent ‘black holes’ on T1‐weighted
MRI images. Although the pathological correlate of black holes is
not entirely clear (van Waesberghe et al, 1999), a recent study
characterizing T1 black holes in demyelinating Theiler’s Murine
Encephalitis Virus infection (Pirko et al, 2004) indicated that the
black holes might resolve as result of a regenerative response.
Thus, one might speculate that at least part of the observations
recorded in the ibudilast trial may have been due to enhanced
remyelination.
In conclusion, our results suggest that pharmacological
inhibition of Pde4 represents a potent and clinically accessible
strategy to promote the endogenous efforts ofmyelin regeneration.MATERIALS AND METHODS
Preparation of primary OPC cultures
Primary OPC cultures were isolated from neonatal Sprague Dawley
(postnatal day 0–2) rat forebrains following a standard protocol
(Baer et al, 2009). Differentiation was induced by Sato’s medium
supplemented with 0.5% foetal calf serum (FCS). For all in vitro
experiments only cultures with 94% purity were used.
Preparation of myelin membrane substrates and myelin
protein extracts
Myelin was puriﬁed following two rounds of discontinuous density
gradient centrifugation and osmotic disintegration as described
previously (Baer et al, 2009; Norton & Poduslo, 1973). The MPE was
prepared by resuspending the myelin pellets in 1% N‐octyl
b‐D‐glucopyranoside, 0.2M sodium phosphate pH 6.8, 0.1M Na2SO4
and 1mM EDTA, and incubated at 23°C for 2 h. Following an
ultracentrifugation step (1,00,000 g, 18°C, 30min) the supernatants
were collected and stored at 80°C until further usage (SyedEMBO Mol Med (2013) 5, 1918–1934
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Figure 9. Pde4 inhibition does not alter the presence of microglia/macrophages in remyelinating lesions
A–C. Scatter plot showing that the number of Macrophage scavenger receptor B (Msr-B)-positive macrophages/microglia was comparable between rolipram-
treated and control animals. Control n¼9, rolipram n¼9; ANOVA: p>0.1; control¼146.827.97, rolipram¼124.518.23. Representative images of
sections stained by in situ hybridization for Msr-B 14 days post lesion induction.
D–F. Similarly, Scatter plot showing that the number of Iba1-positive cells does not differ between the groups 14 days post lesioning. Control n¼4; rolipram
n¼4; t-test; p<0.05; control 124.824.50 cells/mm2, rolipram 104.89.022 cells/mm2. Representative immunohistochemical Iba1 staining.
G–I. Scatter plot and representative images showing that the phagocytic activity in remyelinating lesions at 7 and 14 dpl is comparable. Phagocytic activity
visualized by accumulation of intracellular neutral stained by Oil red O. 7d control n¼8, 7 days rolipram n¼5, 14 days control n¼8, 14 days rolipram n¼5;
Kruskal–Wallis test: p>0.05. Error bars: SEM. Scale bar¼200mm, in insets¼50mm.
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Yasir A. Syed et al.et al, 2008). To test OPC differentiation, slides were coated with MPE
following application of PLL.
Increasing intracellular levels of cAMP
To increase cAMP levels during OPC differentiation in the presence of
MAI the OPCs plated on MPE and control (PLL) substrate were treated
with the membrane‐permeable cAMP analogue dbcAMP (Sigma–
Aldrich). Alternatively, hydrolysis of cAMP was prevented by inhibition
of Pde4 using selective small molecule inhibitors. Drugs tested included
rolipram (Sigma–Aldrich), milrinone (Sigma–Aldrich), irsogladine (Santa
Cruz), zaprinast (Sigma–Aldrich) and rottlerin (Millipore), which were
dissolved according to the manufacturers’ instructions and added to
Sato’s medium. OPCs were differentiated for 48h and then ﬁxed in 4%EMBO Mol Med (2013) 5, 1918–1934 paraformaldehyde (PFA) for immunocytochemistry. A minimum of
three independent experiments was conducted.
Pharmacological inhibition of Erk1/2, p38Mapk and Creb1
The following pharmacological inhibitors were used in the study at
the ﬁnal concentrations indicated: Erk1/2 inhibitor (U0126, 5mM,
Cell Signaling), p38Mapk inhibitor (SB 203580, 10mM, Calbiochem),
CBP‐CREB interaction inhibitor (1.5mM, Calbiochem).
Immunocytochemical analysis in vitro
OPCs were seeded onto PLL‐ or MPE‐coated eight‐well chamber slides
(2104 cells/well). Following 2 days of differentiation, cells were
stained with anti‐O4 (1:100; Millipore Corporation), anti‐Mbp (1:300,2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1929
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Figure 10. Axonal injury following experimental demyelination is comparable between the groups.
A–C. Scatter blot showing comparable levels of non-phosphorylated neurofilament H (Smi32) in rolipram treated and control animals. Control n¼4, rolipram
n¼6, t-test p>0.05; control: 25.002.147, rolipram: 26.541.874. Representative images of Smi32 immunohistochemistry 14 days post lesion
induction.
D–F. Scatter blot demonstrating similar levels of anti-amyloid precursor protein (App) between groups. Control: n¼6; 14 days rolipram: n¼5, t-test p>0.05;
control: 19.333.647, rolipram: 20.196.008. Error bars: SEM. Scale bar¼200mm, in insets¼50mm.
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1930Millipore Corporation) and anti‐A2B5 (1:100; Millipore Corporation)
antibodies (Alexa 488/Alexa555‐conjugated secondary antibody 1:300
dilution, Invitrogen) (Baer et al, 2009; Syed et al, 2011). To assess OPC
differentiation, the percentage of O4/Mbp‐positive cells relative to
>100 DAPI‐stained nuclei per experiment for each condition and each
experiment in randomly selected eye ﬁelds was determined, with the
investigator blind to treatment group. To assess the morphological
phenotype of OPCs, >100 A2B5‐stained cells were categorized as
follows: stage I: mono/bipolar; stage II: multipolar, primary branched;
stage III: multi‐polar, secondary branched; stage IV: secondary
branched cells with membranous processes. Following immunocyto-
chemistry, cells were mounted with Prolong gold antifade mounting
medium (Invitrogen). Cells were visualized and digitalized at ambient
temperature on a LSM 700 confocal microscope (Zeiss) at 20 and
40 magniﬁcation using Zen Application software (Zeiss).
In situ proximity ligation assay
Two days after induction of differentiation, oligodendrocytes were ﬁxed
and incubated with primary antibodies raised in rabbit against p‐Erk1/
2 or p‐p38Mapk and antibodies raised in mouse against p‐Creb1
according to the manufacturer’s protocol (1:150). After three washes in
phosphate‐buffered saline (PBS), the samples were incubated with PLA
probes (species‐speciﬁc secondary antibodies conjugated with a
unique short DNA strand). Close proximity of PLA probes (<40nm)
results in direct interaction by subsequent addition of further DNA
oligonucleotides by enzymatic ligation. Subsequent rolling circle 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.ampliﬁcation using a polymerase results in several hundredfold
replication of DNA circles. Fluorescently labelled complementary
oligonucleotide probes are then used to visualize the nucleotide
polymers. Single molecule ampliﬁcation products can be visualized as
distinct bright signal using a confocal microscope. Negative controls
included incubation of cells with antibodies against each of the proteins
assessed in the absence of antibodies against the proposed binding
partner. Slides were mounted on mounting medium containing 40 ,6‐
diamidino‐2‐phenylindole (DAPI, Olink Biosciences) and assessed on a
confocal microscope. PLA signals are quantiﬁable and this has been
conducted by counting the number stained ‘particles’ in ImageJ.
Assessment of cell viability and apoptosis
Fragmented DNA was detected by TUNEL assay (Promega) and the
percentage of apoptotic nuclei was determined (Baer et al, 2009).
Microarray analysis
RNA was isolated from the oligodendrocytes immediately after shake off
and from those which were differentiated for 4 and 12h in Sato’s
medium containing 0.5% FCS using an RNeasy Mini Kit (Qiagen). The
quality of the RNA was checked with RNA Nano Chips (Agilent) on an
Agilent 2100 Bioanalyzer (Agilent). Additionally, the RNA was puriﬁed
using an RNeasy kit (Qiagen).The RNAwas then prepared and hybridized
to the Rat Exon 1.0ST array (Affymetrix) following protocols provided by
the manufacturer. All raw microarray data are available in MIAME
format from the Geo database (Accession: GSE50042 ID: 200050042).EMBO Mol Med (2013) 5, 1918–1934
The paper explained
PROBLEM:
MS is a devastating disease that involves the loss of myelin, the
protective sheaths around axons that enhance impulse con-
duction. The increasing effectiveness of new drugs that slow the
progression of MS has opened up opportunities for medicines
that enhance remyelination and potentially slow disease
progression even further. Although several new targets for
therapeutic enhancement of remyelination have emerged, few
lend themselves readily to conventional drug development.
RESULTS:
Here, we used transcription-profiling approaches to identify
mitogen-activated protein kinase (Mapk) signalling as an
important regulator involved in the differentiation of OPCs into
oligodendrocytes, the cells that form myelin. We show that
activation of Mapk signalling by elevation of intracellular levels
of the intracellular second messenger cAMP using either a cAMP
analogue or inhibitors of the cAMP-hydrolysing enzyme
phosphodiesterase-4 (Pde4) enhances OPC differentiation in
tissue culture. Finally, we demonstrate that systemic delivery of
a Pde4 inhibitor leads to enhanced differentiation of OPCswithin
focal areas of toxin-induced demyelination and thus to an
acceleration of remyelination.
IMPACT:
This study identifies cAMP-Erk1/2/p38Mapk-Creb1 signalling as
a functionally important intracellular signalling cascade for CNS
remyelination that is regulated at the earliest stages of OPC
differentiation. Our results suggest that inhibiting Pde4 could be
a way to enhance remyelination in chronic demyelinating
diseases, such as MS. Pde4 inhibitors are already approved and
used to treat other diseases, so there is great potential for rapid
translation of this discovery into clinical practice.
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and summarized using the RMA algorithm (Irizarry et al, 2003) as
implemented in the Affymetrix PowerTools software (http://www.
affymetrix.com/partners_programs/programs/developer/tools/powertools.
affx). Probe‐sets that were not called present (Affymetrix signal detection
statistic, p<0.001) in all proﬁles of at least one sample group were
excluded from analysis. Processed data was imported into the R statistical
programming environment (http://www.r‐project.org) and differential
expression between sample groups assessed using the moderated t‐test
(Smyth, 2004) as implemented in the limmapackage for the Bioconductor
suite of R bioinformatics software (http://bioconductor.org). In order to
correct for hypothesis testing on such a scale, p‐values relating to
differential expression were corrected for multiple testing using FDR
correction (Storey & Tibshirani, 2003). Differential expression across
sample groups was deemed signiﬁcant at an FDR of 5% (q<0.05).
Quantitative reverse transcriptase PCR
Total RNA was extracted using an RNeasy Mini Kit (Qiagen). qRT‐PCR
was conducted as previously outlined on (Baer et al, 2009) an Applied
Biosystems 7500HT Fast Real‐time PCR system. Values are represented
as Mbp/b2‐microglobulin ratios. Triplicate measurements were made
on three biological replicates.
Immunoprecipitation and Western blotting
Cells were chilled on ice, washed twice with ice‐cold PBS and lysed in
ice‐cold immunoprecipitation (IP) buffer supplemented with protein
and protease inhibitors (Thermoscientiﬁc). Soluble lysates were
prepared by centrifugation at 14,000 g for 20min at 4°C, and then
incubated with anti‐Erk1/2, anti‐p38Mapk or anti‐Creb antibodies
(Cell Signaling) for 2 h on an orbital shaker. Protein A/G agarose beads
(Santa Cruz) were added and lysate was placed on rocking platform
overnight at 4°C. Immunocomplexes were collected by centrifugation
and washed several times in ice‐cold IP buffer. ImmunoprecipitatedEMBO Mol Med (2013) 5, 1918–1934 proteins were resolved by 12% SDS–PAGE, and immunoblot analysis
was performed according to the manufacturer’s instructions (Invi-
trogen). The blots were incubated overnight with antibodies against p‐
Erk1/2, p‐p38Mapk or p‐Creb. Immunocomplexes were detected by
enhanced chemiluminescence. Following this, the blots blot were
stripped, blocked and reprobed with anti‐Erk1/2, anti‐p38Mapk or
anti‐Creb (Cell Signaling) antibodies.
Induction of focal demyelination
All experiments were conducted in accordance with animal welfare
regulations of the UK Home Ofﬁce and institutional guidelines for
animal care and handling (Project license number: 80/228). Female
Sprague Dawley rats (180–200 g) were anaesthetized using 4%
isoﬂurane in oxygen and positioned in a stereotactic instrument.
Demyelination was induced bilaterally by stereotactic injection of EB
(0.01%, 4ml) into the CCP (10.4mm caudal,2.6mm lateral, and
7.07mm ventral to the bregma (Woodruff & Franklin, 1999). Rolipram
(Sigma–Aldrich) in saline:DMSO 50:50 was administered at a
concentration of 0.5mg/kg/day, and PBS as a control, by implantation
of subcutaneous osmotic minipumps (2ML2, ALZET) 3 days after
surgical lesion induction. Animals were sacriﬁced after 7 and 14dpl. To
rule out effects attributable to the size of the lesion, the density of Plp‐
positive cells was assessed in PBS‐treated animals of this and previous
studies (Syed et al, 2011) by linear regression (GraphPad, Prism). The
inclusion of lesions <0.4mm2, which were strongly populated with
Plp‐positive cells, results in a signiﬁcant non‐zero slope indicating an
effect of the lesion size on the cell density. This may be explained by the
fact that in small lesions recruitment of OPCs and the clearance of
myelin debris is more efﬁcient and thus remyelination becomes more
efﬁcient compared to larger lesions. No signiﬁcant correlation between
the size of the lesion and the density of Plp‐positive cells was observed
in lesions >0.4mm2 area. Consequently, only lesions >0.4mm2 were
included in the analysis.2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1931
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1932In situ hybridization
The expression of a number of marker mRNA species in demyelinated
lesionswas examined by in situ hybridizationwith digoxigenin‐labelled
cRNA probes. Animals were perfused with 4% PFA via the left ventricle.
The tissue was extracted, post‐ﬁxed in 4% PFA, cryoprotected in 30%
sucrose and snap frozen. In situ hybridizations were conducted on
cryostat sections (15mm) using established protocols (Kotter
et al, 2006).
Lesions were identiﬁed on digital images of solochrome cyanine‐
stained sections, and the lesion area was determined using ImageJ
1.43b.The same programwas used to determine the number of stained
cells within the lesions on digitized adjacent sections. All analyses were
conducted investigator blind to treatment group.
Immunohistochemical analysis in vivo
Immunohistochemistry were performed on 10mm‐thick sections of
4% PFA‐ﬁxed tissue. Antigen retrieval was performed with 0.01M
citrate buffer (Dako) at pH 6.0 for 20min in a 95°C water bath. Slides
were allowed to cool for another 20min, followed by rinsing in PBS.
Sections were then incubated with 10% inactivated normal donkey
serum (Abcam) for 60min at room temperature to block background
staining. The cell membrane was permeabilized for 15min in 0.1%
Triton X‐100 in serum. Staining with the following antibodies was
performed: p‐Erk1/2 (1:300), p‐p38Mapk (1:300), p‐Creb (1:300, Cell
Signaling), Nkx2.2 (1:300, U. Iowa), Olig2 (1:1000), App(1:1000,
Millipore), Iba1 (1:500), SMI32 (1:2000, Convance) and Ki67 (1:500,
Dako). Sections were incubated with primary antibody overnight,
washed three times in PBS and then incubated with appropriate Alexa
488‐ or 594‐conjugated secondary antibodies (Invitrogen) for 2 h at
room temperature. They were then counterstained with DAPI (Sigma–
Aldrich). Prolong gold antifade mounting medium (Invitrogen) was
used to mount the slides. Negative controls were performed by
replacing the primary antibody with serum or by incubating sections
with each primary antibody followed by the corresponding secondary
antibody that is not speciﬁc to the species it was raised against. Slides
were examined in a ﬂuorescence microscope (Olympus), and images
were taken by confocal microscopy (Zeiss). All quantiﬁcations
were conducted with the investigators blinded to the treatment
group. Iba1‐positive microglia/macrophages were manually counted
on digitised sections. Automated counting was conducted for Ki67/
Olig2 stained cells. To quantify APP and SMI32 positive axons in the
lesions the area comprised by immunostaining above a calculated
threshold following binary conversion relative to the entire lesion area
was calculated. Only lesions >0.4mm2 were included in the analysis.
Data are given as mean SEM and statistically analysed. Two sections
per marker per animal were analysed and minimum of four animals
were used.
Oil Red O staining
Oil Red O (Sigma–Aldrich) working solution was prepared by adding
20ml dH2O to 30ml 1% Oil Red O in isopropanol. Random sections
from groups were stained for 10min then washed for 4min and
counterstained in Carrazi’s haematoxylin for 4min. Following a 4min
wash in H2O, the sections were differentiated in 0.5% aqueous
hydrochloric acid for 7 s and again washed in water for 10min. Finally,
the slides were mounted using an aqueous mounting medium.
Representative images of Oil Red O stained lesions were digitized and 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.blindly ranked with the highest staining density receiving the highest
rank value. Analyses were conducted with investigator blinded to
treatment group.
Histological analysis of remyelination
To assess the extent of remyelination the tissue, was ﬁxed in 4%
glutaraldehyde, osmicated and processed into resin (TAAB Laboratories)
(Woodruff & Franklin, 1999). Sections (1mm) were stained with 1%
toluidine blue. The extent of remyelination was then assessed by light
and electron (see below) microscopy. Based on the thickness (or
absence) of myelin sheaths demyelinated axons, axons bearing
native myelin sheaths, and remyelinated axons on light and electron
micrographs can unambiguously be distinguished (Blakemore, 1974).
Lesions were ranked according to the extent of remyelination by two
blinded investigators and statistically analysed using a two‐tailed
Mann–Whitney test.
Electron microscopy
Ultra‐thin sections (50 nm) containing the lesions were stained with
aqueous 4% uranylacetate and lead citrate. The sections were
visualized on an electron microscope (Hitachi H‐600 Electron
Microscope). Demyelinated versus remyelinated axons were manually
counted on a minimum of 10 micrographs randomly taken from
the lesion border. Ratios of remyelinated and demyelinated versus the
total number of axons were analysed using Student t‐test. G‐ratios
(¼the ratio of axon circumference to myelin circumference) of
oligodendrocyte‐remyelinated axons were calculated using ImageJ
and statistically analysed. (Lower G‐ratio values indicate thicker myelin
sheaths).
Statistical analysis
Data were analysed using GraphPad software (Prism). Multiple group
comparisons were conducted using one‐way ANOVA followed by
Dunnett’s post test. Analysis of qRT‐PCR data was done using two‐
tailed Student’s t‐tests. For rank analysis a two‐tailed nonparametric
Mann–Whitney U test was used.Author contributions
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